Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SAGE 
Sage Therapeutic (SAGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SAGE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $8.9
1 Year Target Price $8.9
| 0 | Strong Buy |
| 3 | Buy |
| 15 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.16% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 572.99M USD | Price to earnings Ratio - | 1Y Target Price 8.9 |
Price to earnings Ratio - | 1Y Target Price 8.9 | ||
Volume (30-day avg) 19 | Beta 0.17 | 52 Weeks Range 4.62 - 13.47 | Updated Date 06/30/2025 |
52 Weeks Range 4.62 - 13.47 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -476.02% |
Management Effectiveness
Return on Assets (TTM) -36.35% | Return on Equity (TTM) -63.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 160994761 | Price to Sales(TTM) 12.09 |
Enterprise Value 160994761 | Price to Sales(TTM) 12.09 | ||
Enterprise Value to Revenue 3.4 | Enterprise Value to EBITDA -0.33 | Shares Outstanding 62622300 | Shares Floating 51174884 |
Shares Outstanding 62622300 | Shares Floating 51174884 | ||
Percent Insiders 10.41 | Percent Institutions 83.72 |
Analyst Ratings
Rating 4 | Target Price 8.9 | Buy 3 | Strong Buy - |
Buy 3 | Strong Buy - | ||
Hold 15 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sage Therapeutic
Company Overview
History and Background
Sage Therapeutics was founded in 2010 and focuses on developing and commercializing novel medicines to treat brain health disorders. Initially focused on postpartum depression, it has expanded its pipeline to address other neurological and psychiatric conditions.
Core Business Areas
- Neurology: Development and commercialization of therapies for neurological disorders, including epilepsy and Parkinson's disease.
- Psychiatry: Development and commercialization of therapies for psychiatric disorders, including depression, anxiety, and bipolar disorder.
Leadership and Structure
The leadership team includes Barry Greene (CEO), Laura G. Gault (Chief Medical Officer) and Kimi Iguchi (Chief Financial Officer). The company operates with a functional organizational structure focusing on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- Zulresso (brexanolone): Zulresso is an intravenous treatment for postpartum depression (PPD). Zulresso generated approximately $6.1 million in revenue in Q1 2024. Competitors include oral antidepressants and other therapeutic approaches to manage PPD symptoms. There is no direct market share for Zulresso, since itu2019s unique, but the antidepressant market is highly fragmented.
- Zurzuvae (zuranolone): Zurzuvae (zuranolone) is an oral treatment for postpartum depression (PPD). Sage Therapeutics and Biogen co-commercialize this treatment. Sage reported $1.4 million in net product revenue from Zurzuvae in the first quarter of 2024. Competitors include oral antidepressants and other therapeutic approaches to manage PPD symptoms. The market share is evolving following FDA approval in 2023.
Market Dynamics
Industry Overview
The brain health market is growing due to increasing awareness of mental health issues and the need for effective treatments for neurological and psychiatric disorders.
Positioning
Sage Therapeutics is positioned as an innovative biopharmaceutical company specializing in brain health, focusing on novel mechanisms of action.
Total Addressable Market (TAM)
The global market for depression and related disorders is estimated to reach over $16 billion. Sage Therapeutics is positioned to capture a significant portion of this TAM with its novel treatments.
Upturn SWOT Analysis
Strengths
- Novel treatment approaches
- Strong focus on brain health
- Experienced management team
- Partnership with Biogen
Weaknesses
- Limited product portfolio
- Reliance on successful pipeline development
- High cash burn rate
- Commercialization challenges (e.g. Zulresso)
Opportunities
- Expansion into new indications
- Partnerships and collaborations
- Acquisition of complementary technologies
- Increasing awareness of brain health disorders
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
- Pricing pressures
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Eli Lilly (LLY)
- Pfizer (PFE)
Competitive Landscape
Sage Therapeutics has a novel approach but struggles with commercialization. Competitors such as Biogen, Eli Lilly, and Pfizer have greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been largely driven by pipeline progress and regulatory approvals.
Future Projections: Future growth is dependent on successful clinical trials and commercialization of pipeline products, with analysts projecting revenue increases over the next few years.
Recent Initiatives: Focus on pipeline development, including SAGE-718 for neurological disorders, and commercial expansion of Zurzuvae. Partnerships with Biogen are also key.
Summary
Sage Therapeutics is a biotechnology company pioneering brain health treatments, but its commercial success is not yet proven given the losses that the company has taken. A key strength is its novel treatment approach, but struggles with commercialization. The company is at a pivotal moment with continued regulatory approvals and pipeline advancements, particularly with its partnership with Biogen and SAGE-718.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sage Therapeutic
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2014-07-18 | President, CEO & Director Mr. Barry E. Greene | ||
Sector Healthcare | Industry Biotechnology | Full time employees 353 | Website https://www.sagerx.com |
Full time employees 353 | Website https://www.sagerx.com | ||
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.